Resource Filter: Drug Development
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma
Date
Profiling the tumor microenvironment through same-section fully automated spatial multiomics
Date
WTX-712, a Conditionally Active IL-21 INDUKINETM Molecule, Induces a Strong Anti-tumor Phenotype Through a Differentiated Mechanism
Date
Discovery of WTX-518, an IL-18 Pro-drug That is Conditionally Activated Within the Tumor Microenvironment and Induces Regressions in Mouse Tumor Models
Date
Optimal Antitumor Immunity is Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINE™ Molecule that Releases Fully Potent IL-2 into the Tumor Microenvironment
Date
Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) or IL-2 (WTX-124) INDUKINE™ Molecules
Date
The Combination of ACT and INDUKINE™ Therapy Leads to Improved Antitumor Immunity in Mouse Solid Tumors
Date
Development of WTX-712, a Conditionally Active IL-21 INDUKINETM Molecule for the Treatment of Cancer
Date
